Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care with Current and Emerging Management Strategies

It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which provide a new option for managing relapsed disease. In this animated, visually enhanced activity, a hematology-oncology expert outlines the clinically relevant mechanistic aspects of covalent and noncovalent BTK inhibitors, mechanisms and patterns of resistance to covalent agents, and rationale for integrating novel approaches to combatting resistance and intolerance.

In this activity, an allergy expert discusses the mechanism of action and current treatment approaches for managing IgE-mediated food allergies.

Medical Learning Institute, Inc., the Endocrine Society, and the National Committee for Quality Assurance are offering 2 live social media-based educational activities that will recap key points and address questions from clinicians regarding the optimal use of mealtime insulin to control blood glucose levels.

Medical Learning Institute, Inc., the Endocrine Society, and the National Committee for Quality Assurance are offering 2 live social media-based educational activities that will recap key points and address questions from clinicians regarding the optimal use of mealtime insulin to control blood glucose levels.

In this activity, an expert in eosinophilic esophagitis discusses the latest research, data, and guidelines on novel and emerging targeted therapies.

In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU).

Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGCT presentations, and illustrate the nuances of multidisciplinary collaboration when managing patients with TGCT. Throughout, the panelists profile a modern management synthesis that combines surgery, physical therapy, and the use of targeted agents, including for patients for whom surgery alone is unlikely to be beneficial.

In this activity, an expert in neurology discusses emerging treatment options for patients with amyotrophic lateral sclerosis.

In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children.

In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making.